FDA 483 - Lupin Limited - January 25, 2019

An FDA inspection of Lupin Limited in Pithampur, India, revealed significant deficiencies across multiple areas of drug manufacturing. The firm failed to adequately investigate out-of-specification results and customer complaints, lacked proper employee training and management oversight, and demonstrated poor control over computer systems and equipment validation. These issues indicate a systemic breakdown in quality control and data integrity practices.